Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir Alafenamide
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT04636437. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study was to determine if people with HIV and obesity taking an antiretroviral treatment regimen containing an integrase strand transfer inhibitor (INSTI) with (tenofovir alafenamide/emtricitabine (TAF/FTC) would either slow their rate of weight gain, or even lose weight, over the span of about 1 year after a switch to a regimen containing doravirine (DOR; a newer, non-nucleoside reverse transcriptase inhibitor medication) combined with either TAF/TFC or tenofovir disoproxil fumarate (TDF)/FTC.
Study identification
- NCT ID
- NCT04636437
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 147 participants
Conditions and interventions
Conditions
Interventions
- Doravirine 100 Mg Drug
- Integrase strand transfer inhibitors Drug
- Tenofovir alafenamide/emtricitabine Drug
- tenofovir disproxil fumarate/emtricitabine Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 27, 2021 (Actual)
- Primary completion
- Oct 18, 2024 (Actual)
- Completion
- Oct 18, 2024 (Actual)
- Last update posted
- Jul 2, 2025
2021 – 2024
United States locations
- U.S. sites
- 27
- U.S. states
- 17
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alabama CRS (31788) | Birmingham | Alabama | 35294 | — |
| UCLA CARE Center CRS (601) | Los Angeles | California | 90095 | — |
| UCSD Antiviral Research Center CRS (701) | San Diego | California | 92103 | — |
| Ucsf Hiv/Aids Crs (801) | San Francisco | California | 94110 | — |
| Harbor-UCLA CRS (603) | Torrance | California | 90502 | — |
| University of Colorado Hospital CRS (6101) | Aurora | Colorado | 80045 | — |
| Whitman-Walker Institute, Inc. CRS (31791) | Washington D.C. | District of Columbia | 20005 | — |
| The Ponce de Leon Center CRS (5802) | Atlanta | Georgia | 30308 | — |
| Northwestern University CRS (2701) | Chicago | Illinois | 60611 | — |
| Johns Hopkins University CRS (201) | Baltimore | Maryland | 21205 | — |
| Massachusetts General Hospital (MGH) CRS (101) | Boston | Massachusetts | 02114 | — |
| Brigham and Women's Hosp. ACTG CRS (107) | Boston | Massachusetts | 02115 | — |
| Washington University Therapeutics (WT) CRS (2101) | St Louis | Missouri | 63110 | — |
| New Jersey Medical School Clinical Research Center CRS (31786) | Newark | New Jersey | 07103 | — |
| Weill Cornell Chelsea CRS (7804) | New York | New York | 10010 | — |
| Columbia Physicians and Surgeons (P&S) CRS (30329) | New York | New York | 10032 | — |
| Weill Cornell Upton CRS (7803) | New York | New York | 10065 | — |
| University of Rochester Adult HIV Therapeutic Strategies Network CRS (31787) | Rochester | New York | 14642 | — |
| Chapel Hill CRS (3201) | Chapel Hill | North Carolina | 27514 | — |
| Greensboro CRS (3203) | Greensboro | North Carolina | 27401 | — |
| Cincinnati CRS (2401) | Cincinnati | Ohio | 45267 | — |
| Case CRS (2501) | Cleveland | Ohio | 44106 | — |
| Ohio State University CRS (2301) | Columbus | Ohio | 43210 | — |
| Penn Therapeutics CRS (6201) | Philadelphia | Pennsylvania | 19104 | — |
| Vanderbilt Therapeutics (VT) CRS (3652) | Nashville | Tennessee | 37204 | — |
| Houston AIDS Research Team CRS (31473) | Houston | Texas | 77030 | — |
| University of Washington Positive Research CRS (1401) | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04636437, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 2, 2025 · Synced Nov 15, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.